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ABSTRACT

The Micronutrient Profile of the Typical American Diet Enhances
Colorectal Carcinogenesis

by

Stephany Perez Monsanto, Master of Science
Utah State University, 2013

Major Professor: Dr. Abby D. Benninghoff
Department: Animal, Dairy and Veterinary Sciences

The typical Western dietary pattern is characterized by the consumption of
energy-dense, nutrient-poor foods and has been linked to increased risk of colorectal
cancer (CRC). Our research group previously developed the total Western diet (TWD)
that emulates typical human dietary intakes of macro- (carbohydrates, proteins, and fats)
and micronutrients (vitamins and minerals) on an energy density basis for rodents. In the
present study, we sought to determine the impact of TWD on biomarkers of metabolic
syndrome and obesity in comparison to a commercial 45% fat diet used for models of
diet-induced obesity (DIO diet) and the standard basal AIN93G diet, which is optimized
for rodent health. Also, we included 2 additional test diets to evaluate the contribution of
the micronutrient (vitamin- and mineral-modified diet, [VMM]) or macronutrient (macromodified diet [MM]) contents of the TWD in development of cancer, obesity, and
glucose intolerance. A chemical carcinogenesis model of inflammation-associated colon
cancer was employed to evaluate impact of diets on colon cancer in mice. As expected,
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mice consuming the DIO diet acquired an obesity/metabolic syndrome phenotype
typified by increased food energy intake, greater rate of body weight gain, increased
proportion of body composition as fat mass, higher fasting glucose, impaired glucose
tolerance, and higher circulating levels of leptin. However, consumption of TWD did not
alter any of these classic biomarkers of metabolic health, as these mice adjusted food
intake so that energy consumption was similar to that for mice fed AIN93G. A different
pattern was observed for colon carcinogenesis. Consumption of the TWD or VMM diet
markedly increased colon tumor multiplicity and size compared to the AIN93G control,
whereas consumption of the DIO or MM diets did not enhance colon tumorigenesis.
Collectively, these observations point to a critical role of dietary micronutrients in colon
carcinogenesis, and that this promoting effect is likely unrelated to the metabolic
syndrome phenotype induced by a high fat diet. Moreover, our observations emphasize
the need to take into account the micronutrient content of rodent basal diets when
modeling typical U.S. nutrition in pre-clinical animal experiments in order to improve the
translation of these studies to human nutrition and dietary intervention programs.
(93 pages)
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PUBLIC ABSTRACT

The Micronutrient Profile of the Typical American Diet Enhances
Colorectal Carcinogenesis

by

Stephany Perez Monsanto, Master of Science
Utah State University, 2013

The typical Western dietary pattern is characterized by the consumption of highenergy foods that are low in essential nutrients and has been linked to increased risk of
colorectal cancer (CRC). Our research group previously developed the total Western diet
(TWD) to emulate typical human dietary intakes of macro- (carbohydrates, proteins, and
fats) and micronutrients (vitamins and minerals) based on food energy basis for rodents.
In the present study, we sought to determine the impact of TWD on indicators of
metabolic syndrome and obesity in comparison to a commercial 45% fat diet used for
models of diet-induced obesity (DIO diet) and the standard basal AIN93G diet, which is
optimized for rodent health. Also, we included 2 additional test diets to evaluate the
contribution of the micronutrient (vitamin- and mineral-modified diet, [VMM]) or
macronutrient (macro-modified diet [MM]) contents of the TWD in development of
cancer, obesity, and glucose intolerance. We employed a chemical carcinogen model of
colon cancer in mice with an agent to induce inflammation of the gastrointestinal tract to
evaluate the impact of these experimental diets on formation of colon tumors. As
expected, mice consuming the DIO diet gained excess weight and had symptoms typical
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of metabolic syndrome, including greater rate of body weight gain, increased proportion
of body fat mass, higher levels of blood glucose, impaired glucose tolerance, and higher
circulating levels of the hormone leptin. However, consumption of TWD did not alter any
of these biomarkers of metabolic health, as these mice adjusted food intake so that energy
consumption was similar to that for mice fed AIN93G. Conversely, consumption of the
TWD or VMM diet markedly increased colon tumor number and size compared to the
AIN93G control, whereas consumption of the DIO or MM diets did not enhance colon
tumor formation. Collectively, these observations point to a critical role of micronutrients
in the development of colon cancer, and that this promoting effect is likely unrelated to
the metabolic syndrome symptoms acquired by mice consuming strictly a high fat diet.
Moreover, our observations emphasize the need to take into account the micronutrient
content of rodent basal diets when modeling typical U.S. nutrition in pre-clinical animal
experiments in order to improve the translation of these studies to human nutrition and
dietary intervention programs.
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INTRODUCTION

Colorectal cancer is the third leading cause of cancer death and the third most
commonly diagnosed cancer in men and women in the United States (1). In the last
twenty years, global incidence rates of colorectal cancer have been increasing, reportedly
due to an increase in the prevalence of certain cancer-associated practices, such as
decreased physical activity and “westernized” diets (2). The typical Western Diet is a
dietary trend characterized by increased consumption of highly processed foods that
contain excess levels of fat, sodium, and refined sugars and are generally low in essential
vitamins, minerals, and fiber (3-5). This dietary pattern is believed to play a critical role
in the development of several chronic conditions that have increased in prevalence over
the last 50 years, including obesity, type II diabetes, metabolic syndrome (5, 6) as well as
colorectal cancer (7-9). Because of the increasing socioeconomic burden of colorectal
cancer, a large body of research has been dedicated to the study of the role of nutrition on
the development of this and other related conditions with the purpose of elucidating the
mechanisms behind their pathology.

Statistics on colorectal cancer
Colorectal cancer (CRC) is the fourth most common cause of death worldwide,
with approximately 608,000 deaths occurring each year (10). Global incidences of CRC
have increased over the last twenty years, and this disease is more prevalent in
economically developed countries, which account for up to 60% of reported cases (2, 10).
The lifetime risk of developing CRC in the U.S. is about 5%, and the risk is slightly
lower in women than in men. Based on the level of economic development of the region,
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Central and Eastern Europe are estimated to have the highest mortality rates in both sexes
(20.1 for male, 12.2 for female per 100,000), while Middle Africa is estimated to have the
lowest mortality rate (3.5 for male, 2.7 for female). In the United States, significant
improvements in colorectal screening and treatment methods have caused mortality rates
to decrease 2.8% per year in men and 2.6% per year in women since 1998. However,
according to data collected between 1975 and 2007 from the Surveillance, Epidemiology,
and End Results (SEER) Program, colorectal cancer incidence rates have declined in the
U.S. among adults 50 years and older, but have increased among adults younger than 50
years (1). Although the precise cause for this trend remains a topic of debate, current data
point to several environmental factors as potential contributors to these apparent shifts in
cancer risk.

Risk factors for colorectal cancer
CRC risk is influenced by external modifiable factors (lifestyle and diet) and
intrinsic non-modifiable factors (genetic predisposition). Heredity accounts for
approximately 30% of all the diagnosed cases of CRC, of which 5% are attributed to
well-characterized heritable genetic defects (11, 12). The remaining cases are generally
attributed to either single-gene mutations that are less pervasive than those observed in
well-characterized syndromes, or mutations on multiple susceptibility loci that result in
additive effects. However, several hereditary syndromes are well described and have
been strongly linked with CRC development.
Lynch Syndrome (or hereditary nonpolyposis colorectal cancer) is an autosomal
dominant cancer-susceptibility disorder caused primarily by germline mutations of
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mismatch repair genes. Although it predisposes subjects to several other types of cancers,
it accounts for about 3% of CRC cases and can increase CRC risk as much as 80%
depending on the type of mutation (11, 13).
Familial adenomatous polyposis (FAP) is one of the best-studied polyp-forming
syndromes, although it accounts for less than 1% of CRC cases (11, 14). FAP is an
autosomal dominant disease that results from germline mutations in the APC gene. The
severity of the condition varies depending on the location of the mutation within the APC
gene, which produces other variants of the condition (i.e. Attenuated FAP, Gardner
syndrome, and Turcot syndrome).
MUTYH-associated polyposis (MAP) is a germline inactivation of the base
excision repair gene MUTYH (or MYH), which causes adenomatous polyposis of the
colorectum and an increased risk of CRC. In patients carrying this mutation, the risk of
CRC is nearly 100% by 60 years of age (11, 15).
Hamartomatous polyposis syndromes are a group of inherited conditions that
exhibit varying individual characteristics, but commonly show hamartomatous rather than
epithelial polyp histology. Disease-associated mutations occur in different genes, some of
which are STK11, SMAD4, and BMPR1A. Individuals with any of the related conditions
have an increased risk for several types of cancer, including CRC. These syndromes
account for less than 1% of CRC cases (11, 16).
Familial non-syndromic colorectal cancer refers to any CRC cases involving an
uncommon genetic defect that is sufficiently penetrant to give rise to an autosomaldominant segregation pattern. Thus, specific genetic markers for these cases are not
available. Risk of CRC is approximately 2- to 3-fold greater for an individual with a first-
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degree relative that has been diagnosed with CRC after age 50. The disease can be caused
by genetic polymorphisms, allelic variants, chromosomal instability, aberrant DNA
methylation, and other environmental factors (11, 15, 17).
Finally, another critical non-modifiable risk factor for CRC is individual medical
history. Individuals who have been previously diagnosed with CRC (even if they have
recovered), who have had one or more adenomatous polyps, who suffer from
inflammatory conditions (e.g. Crohn’s disease, ulcerative colitis, and inflammatory bowel
disease), or who suffer from a condition strongly associated with CRC (e.g. Type II
diabetes or obesity), have an increased risk of developing CRC (1, 18). Additional
conditions that have been strongly associated with an increased risk of CRC include
obesity (9, 19, 20), metabolic syndrome (8, 21, 22), diabetes (23-25), and nonalcoholic
fatty liver disease (7, 26, 27).
Lifestyle and diet are external modifiable factors that greatly influence CRC risk
and disease progression, and global patterns of CRC incidence closely align with patterns
of physical activity and dietary trends. High levels of physical activity have been
associated with lower CRC risk and lower mortality (1, 28, 29), even after CRC diagnosis
(30). Data for 2005 from the Centers for Disease Control and Prevention (CDC) show
that more than half of U.S. adults fail to meet the amounts of physical activity
recommended by the CDC and the American College of Sports Medicine (31), a figure
that correlates with the high rates of CRC reported in the U.S.
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Animal models of colorectal carcinogenesis
In general, most pre-clinical studies of CRC employ a either a chemical
carcinogenesis animal model, in which the hydrazine compounds 1,2-dimethylhydrazine
(DMH) or its metabolite azoxymethane (AOM) are used to induce sporadic tumors in the
colon, or a transgenic animal model, wherein mice carry a heterozygous mutation in the
adenomatous polyposis coli (APC) gene leading to development of tumors in the small
intestine and colon (see 32 for a comprehensive review). The most widely used
transgenic model of intestinal and colon cancer is the APCMin/+ mouse (33). The APC
gene regulates various cellular pathways, including Wnt-signaling (involved in cell
proliferation), cell-cell adhesion, cell cycle progression, and apoptosis. When one or
several of these pathways are disrupted via mutation, the cell could escape normal
constraints on cell proliferation and acquire a survival advantage. For this reason, a
mutation in the APC gene is considered one of the most important initiating events in
sporadic CRC (34). The defining feature of this cancer model is a nonsense mutation that
results in a truncated APC protein at amino acid 850, which induces the formation of
polyps in the mouse intestine. The majority of these polyps develop in the small intestine,
which is why this model is deemed more useful for the study of hereditary colon cancer
types, such as FAP. However, others have developed modifications of this transgene to
improve the cancer model so that it more closely emulates human CRC, including a)
modifiers of Min (Mom), which comprise several loci located on different chromosomes
which have an effect of tumor development (e.g. mom1, mom2); b) Apc variations, which
include different truncations to the Apc protein (e.g. ApcΔ716/+; ApcΔ14); and c) compound
mutants, which add a mutation to another gene (e.g. mismatch repair genes, Smad1) (33).
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Chemically induced models of CRC are advantageous because they are highly
reproducible, and the approach allows for testing on animals with different genetic
backgrounds. Importantly, the pattern of cancer development in these models generally
mimics the multistep process of carcinogenesis observed in human CRC, and most
tumors develop in the distal colon. A number of chemicals have been show to effectively
induce carcinogenesis in the colons of rats and/or mice, including the aforementioned
hydrazine compounds DMH and AOM; some heterocyclic amines, such as 2-amino-1methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-33-methylimidazo[4,5f]quinolone (IQ); and the alkylnitrosamide compounds methylnitrosourea (MNU) and Nmethyl-N’-nitro-N-nitrosoguanidine (MNNG). AOM is now the most widely used
chemical carcinogen for modeling sporadic colorectal cancer in rodents. AOM undergoes
metabolic activation in the liver by the cytochrome P450 enzyme CYP2E1 to form the
metabolite methylazoxymethane (MAM), which can readily generate a methyldiazonium
ion that can alkylate DNA at the O6 or N7 position of guanine (35).
Disruption of the canonical Wnt/β-catenin signaling pathway is often observed in
animals initiated with AOM (reviewed in 36, 37). The protein β-catenin aides in cell
adhesion by associating with either cadherin or catenin to connect the actin cytoskeleton;
it also acts as a co-transcriptional activator of genes that are under regulation of the Wnt
signaling pathway. AOM exposure can lead to mutations in codons 31 and 41 of βcatenin, which prevents its degradation (37). Accumulation of the protein leads to
transcriptional activation of a number of downstream gene targets that promote cell
proliferation, such as cyclin D1 (38). AOM exposure also leads to mutations in the protooncogene K-ras, a small G protein that regulates both mitogen-activated protein kinase
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(MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt intracellular signaling pathways,
resulting in dysregulation of cell growth, proliferation, and glucose metabolism (39). One
of the hallmarks of sporadic and AOM-induced colon cancer is perturbation of the
transforming growth factor-β (TGF-β) signaling cascade. TGF-β is an important antiinflammatory cytokine expressed in colon epithelial cells and serves as a key negative
regulator of cell proliferation via control of cell growth and apoptotic pathways. The
tumor suppressor function of TGF-β1 is often lost during tumorigenesis (32). Aberrant
signaling of the TGF-β1 pathway has been shown in the AOM colon cancer model.
Disruption of TGF-β1 signaling is characterized by decreased ratios of biologically active
to inactive TGF-β1 in tumor cells (40), along with transcriptional repression of the TGFβ1 receptor TβR-II (41).
Sensitivity to AOM as a chemical carcinogen is highly influenced by the genetic
background of the animal model used, as well as the route and frequency of
administration (32, 42, 43). For example, SWR/J and A/J mouse strains are highly
susceptible to AOM-induced tumors (16 to 36 tumors/mm colon following 8 repeated i.p.
injections of 10 mg/kg AOM) compared to AKR/J mice, which are very insensitive (<1
tumor/mm colon) (43). Also, it should be noted that colon carcinogenesis does not appear
to be influenced by gender, as similar incidence, multiplicity, and size of tumors in males
and females have been observed previously (42).
Data from epidemiological studies have shown that CRC risk is strongly linked to
long-term irritable bowel diseases (IBD), of which the most common types are Crohn’s
disease and Ulcerative colitis (44-46). The chronic intestinal inflammation that
characterizes these conditions is now recognized as an important factor in CRC due to its
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involvement in the disruption of the same oncogenic pathways that are disrupted in CRC
(47). Both Crohn’s disease and ulcerative colitis are caused by the mutation of several
genes involved in the maintenance of the intestinal mucosal barrier that protects the
intestinal wall from bacterial invasion. Dysfunction of this mucosal barrier leads to
sustained damage of gut epithelial cells. This chronic injury to the gut triggers a
compensatory immune response characterized by the up-regulation of cell proliferation
and anti-apoptotic pathways that promote cell survival (48). Various molecules are
involved in the activation of such pathways, including transcription factors (e.g. NF-κB,
and STAT3), and various inflammatory cytokines (e.g. IL-6 and TNF- α), which are
normally secreted during an inflammatory response. The resulting compensatory cell
regeneration results in increased rates of mitosis that, when chronically active, increase
DNA mutation rates (48, 49). Not only can this process promote the disruption of
oncogenic pathways, but it can also provide cancerous cells with a nurturing environment
due to the increased availability of proliferative and survival signals. This notion is
supported by an animal study by Tanaka et al. (50), where they showed that a combined
treatment of AOM with the inflammatory agent dextran sodium sulfate (DSS)
significantly increased intestinal tumorigenesis in CD-1 mice. The AOM+DSS model
yields a consistent, reproducible colon cancer outcome that is well defined in terms of
mouse strain and AOM dosage (51). Moreover, this model recapitulates many of the
molecular events that occur in spontaneous human colon cancer, such as -catenin
accumulation and K-ras mutations (37).
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Dietary factors that promote colorectal carcinogenesis
Diet is one of the most influential factors affecting overall cancer incidence, with
colorectal cancer being one of the most well established examples. The Western diet is
characterized by high intakes of red and processed meats, fried foods, sweet foods (often
in the form of soft drinks), and refined grains (5). Conversely, those consuming a western
type diet typically have low intakes of fruits, vegetables, and fish. Overall, this food
consumption pattern results in an unbalanced diet that is high in simple sugars, fats, and
sodium yet low in many essential vitamins, minerals, and fiber (3). Evidence from
epidemiological and pre-clinical animal studies supports the notion that the Western diet
is positively associated to a higher risk and incidence of colorectal cancer (3, 5).
Many elements of a Western diet have been associated with higher rates of CRC.
In developed countries, excess consumption of red meat has been linked to higher
incidence of CRC (4, 52-54). Evidence from human case-control and cohort studies
points to a positive correlation between high red meat consumption and CRC risk. A 6year follow-up study using a cohort of 47,949 men from the Health Professionals study
determined that consumption of beef, pork, and lamb had a strong positive association
with CRC risk (53). Norat et al. showed that CRC risk was significantly associated with
pork and lamb consumption in a separate 5-year cohort study of 478,040 men and women
from Western Europe (54). This association between red meat consumption and CRC risk
has been attributed, in part, to the presence of N-nitroso compounds, which are known
alkylating agents (52, 55, 56). Also, red meat naturally contains high levels of heme,
which generates reactive oxygen species (52, 57). Finally, well-cooked or preserved
meats can contain high amounts of mutagenic heterocyclic amines (52, 56, 57).
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Overall, evidence for a role of dietary fat in the etiology of CRC in humans is
inconsistent. In the previously mentioned Health Professionals Follow-up Study cohort,
fat from red meat was positively associated with higher CRC risk in men, while no
association was observed for total fat or non-red meat fat intake (i.e. poultry, dairy, and
vegetable) (53). Willett and coworkers reported that intakes of animal-derived saturated
and monounsaturated fats were linked to increased risk of CRC in a prospective study of
mid-age, healthy women (58). Alternatively, Lin et al. (59) reported that neither total fat
intake nor intakes of different types of fats or major fatty acids were related to risk of
CRC in healthy women. Moreover, in a combined analysis of 13 case-control studies
including 5,287 cases of CRC and 10,470 controls, no evidence of increased risk was
observed for any dietary fat variable after adjustment for total food energy intake or after
subgroup analyses by sex, age, or anatomic location of the cancer (60).
In contrast to human data, the association between dietary fat intake and CRC
promotion has been repeatedly demonstrated in different rodent models of colorectal
carcinogenesis. As outlined above, chronic intestinal inflammation is a known risk factor
for CRC. Researchers have repeatedly shown that intestinal inflammation is enhanced in
C57BL/6J mice fed with diets with 20% (61), 45% (62), or 60% kcal from fat (63). In
chemical carcinogenesis rodent studies, researchers often measure development of
preneoplastic lesions, termed aberrant crypt foci (ACF), as a biomarker of colorectal
carcinogenesis. Development of these lesions, as well as fully developed colon tumors,
has been linked to specific sources of dietary fat. For example, ACF multiplicity was
significantly higher in the colons of rats fed diets containing 10 or 20% corn oil
compared to animals consuming diets with 10% or 20% fish oil (38, 64). Evidence from
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other rat cancer studies suggests that tumor abundance was also greater in animals fed
corn oil (38, 65) or beef fat (38, 66). On the other hand, consumption of fish or flaxseed
oil provided protection against colon carcinogenesis in rodents (67-70). Collectively,
these animal studies provide convincing evidence that the source of dietary fat, rather
than total fat intake, is the driving factor for modulating colon carcinogenesis in rodents.
A number studies have indicated that CRC risk is inversely correlated to the
consumption of vegetables, fruits, and/or fiber, which are essential components of a
balanced diet (71). However, current data is not completely consistent, suggesting that
other interacting factors are likely modulating their effects. For instance, a prospective
study including 136,089 men and women from the Nurses’ Health Study and Health
Professionals’ Follow-up Study found no correlation between fruit and vegetable
consumption, and colon or rectal cancer incidence (72). A meta-analysis of data from 13
cohort studies analyzed in the Pooling Project of Prospective Studies of Diet and Cancer
examined the association between dietary fiber intake and CRC risk. The authors
observed that risk of colorectal cancer in an age-adjusted model was inversely associated
with dietary fiber intake, although this association was no longer significant after
adjusting for other risk factors (73). Conversely, a 5-year follow up study of 133,163 U.S.
men and women examined the association between whole grains, fruit, vegetables, and
dietary fiber and CRC (74). Although no independent association was observed between
whole grains, fruit, or fiber and incidence of CRC, very low consumption of vegetables
and ﬁber was associated with a 2-fold increase in the risk of colon cancer in men, while
very low consumption of fruit was associated with a doubling of risk in women. In a
separate meta-analysis of data from the Pooling Project of Prospective Studies of Diet
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and Cancer, epidemiologists arrived at a similar conclusion, where the lowest intakes of
fruits and vegetables (less than 200 g/day) were inversely associated with an elevated risk
for distal colon cancer risk, but not proximal colon cancer (75). Finally, to examine the
associations between food patterns and CRC incidence in older Americans, Wirfalt et al.
(76) performed a cluster analysis in which individuals with similar characteristics were
aggregated. Male subjects that consumed high amounts of fruits, vegetables, and low fat
foods were less likely to develop CRC, even when considering other disease risk factors.
On the other hand, female subjects in this “Vegetable and Fruit” cluster had lower CRC
incidence, but not independently of other risk factors such as education, smoking, and
ethnicity.
Much of the evidence for a role of specific micronutrients in modulation of CRC
centers on calcium and vitamin D, the latter referring collectively to a group of
secosteroid molecules that are critical for the uptake of calcium in the intestine. D
vitamins include cholecalciferol (vitamin D3), which is generally synthesized
endogenously in response to ultraviolet light, usually in adequate amounts. However,
some individuals do not obtain sufficient light exposure to maintain adequate levels of
D3, which is often fortified in staple foods, such as milk, to avoid deficiency (77).
Overall, evidence from human epidemiological and animal laboratory studies points to
lower risk of CRC for high intakes of calcium and vitamin D, particularly for senior
women. Feskanich et al. (78), examined CRC risk in a nested case-control study among
women participating in the Nurses’ Health Study and determined that women ≥ 60 years
of age with the plasma levels of 25-hydroxycholecalciferol (25(OH)D), a metabolite of
D3 and the precursor to the bioactive form 1,25-dihydroxycolecalciferol (1,25(OH)2D),
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had a much lower risk of CRC compared to subjects in the lowest quintile of 25(OH)D
levels. Alternatively, this inverse relationship between circulating 25(OH)D and CRC
risk was not observed in younger women. Lappe et al. (79) examined CRC in healthy,
post-menopausal women receiving either a calcium supplement (1500 mg), a calcium
supplement with 1100 IU vitamin D3,or a placebo. Women receiving the dual calcium
and vitamin D supplement or the calcium supplement alone were more likely to remain
cancer-free (breast, colon, lung, uterus, and hematopoietic cancers were examined)
during the 6-year analysis period. Park et al. (80) examined CRC risk as a function of
dietary calcium and vitamin D intakes, dairy food consumption, and gender and ethnicity
in the large Multiethnic Cohort Study of more than 215,000 participants. This group
observed that total calcium intake and consumption of dairy foods were inversely
correlated with CRC risk in both healthy men and women, and that this relationship for
calcium was consistent across the ethnic groups examined (African Americans, Native
Hawaiians, Japanese Americans, Latinos, and Whites). Vitamin D was also found to have
protective effects in those individuals who do not supplement their diet with additional
calcium. Evidence from animal studies supports these epidemiological observations.
Depletion of calcium from the rodent diet increased spontaneous tumor formation while
vitamin D supplementation inhibited tumorigenesis in C57BL/6J (81) and in Apc1638N/+
mice (82).
Much of the research on B vitamins and CRC development has focused on
vitamin B9 (folate), vitamin B6 (pyridoxal phosphate), and vitamin B12 (cobalamin), due
to their function in the methyl donor pathway and one-carbon metabolism (83, 84). Folate
is a required for the synthesis, repair, and methylation of DNA, but current data on folate
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intake and CRC development are inconsistent. In human studies, higher folate intakes are
generally associated with reduced CRC risk, but data from animal studies suggests that
the dose and timing of folate intervention differentially modulate carcinogenesis. For
instance, Sanjoaquin and coworkers (85) performed a meta-analysis that included 7
cohort and 9 case control studies and found that CRC risk was 25% lower among those in
the highest category of food-derived folate intake compared with those in the lowest
category. When analyzing total folate intake (food-derived and supplemented folate),
only a 5% lower risk was observed. A separate meta-analysis that included 18 case
control studies and 9 cohort studies from fourteen countries found that CRC incidence
was decreased 13-18% in the highest quintile of dietary folate intake (86). However, in a
study where AOM treated rats were given one of 3 diets containing 0, 2, or 8 mg folic
acid/kg diet, the total number of colonic ACF increased with rising dietary folic acid
concentration. The total number of colonic ACF was 54% higher in rats fed the 8 mg/kg
diet than in the rats receiving the 0 mg folic acid/kg diet, suggesting that folic acid
enhanced colorectal tumorigenesis (87). A separate study using C57BL/6J mice
determined that colon carcinogenesis was largely unaffected by supplementation with
dietary folate, although higher intakes of folic acid were linked to a higher proportion of
relatively large tumors (88). Moreover, neither plasma nor colon folate levels were
significantly correlated with tumor number (88).
The role of vitamin B6 in the etiology or prevention of CRC is also unclear. Je et
al. (89) performed a meta-analysis of 472 cases of CRC detailed in the Nurses’ Health
Study, the Health Professionals Follow-up Study, and the Physicians’ Health Study and
found no association with plasma levels of pyridoxal 5’-phosphate, the active form of B6,
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and CRC mortality. In a meta-analysis of 8 studies on vitamin B6 intake and 4 studies on
blood pyridoxal 5’-phosphate levels, Larsson et al. showed that both factors were
inversely associated with the risk of colorectal cancer (90). Risk of CRC decreased by
49% for every 100-pmol/mL increase in blood pyridoxal 5’-phosphate level, while high
vitamin B6 intake was associated with a 20% decreased risk compared to low intake.
Finally, in CD-1 mice, supplementation with 35 mg of pyridoxine HCl markedly reduced
CRC incidence compared to a diet depleted in B6 (91).
Because of its key role as a cofactor in the one carbon metabolism pathway, many
researchers have included vitamin B12 in cancer prevention studies. However, like many
other micronutrients, the role of this particular vitamin in colorectal carcinogenesis
remains uncertain. In a follow-up study including 226 cases and double matched referents
from the population-based Northern Sweden Health and Disease Study, Dahlin and
colleagues found that plasma vitamin B12 concentrations were inversely associated with
the risk of rectal cancer, while the association was less clear for colon cancer (92). These
results are in agreement with an animal study by Choi and colleagues (93), where 30
Sprague-Dawley rats were fed with either a diet with 50 μg/kg diet of vitamin B12, or a
diet with no vitamin B12. After 10 wk, the colonic DNA of the deficient rats displayed a
35% decrease in genomic methylation and a 105% increase in base substitution of uracil,
which are anomalies that may increase the risk of colorectal carcinogenesis. In other
studies, researchers often use a combination of vitamin B12 , folate, and vitamin B6, since
these are all essential components of the one-carbon metabolism pathway, and hence act
in conjunction. In a randomized, double-blind, placebo-controlled trial, 1,470 female
health professionals from the Women’s Antioxidant and Folic Acid Cardiovascular Study
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were randomly assigned to receive either a placebo or a combination pill of folic acid (2.5
mg), vitamin B6 (50 mg), and vitamin B12 (1 mg). Researchers found no significant
differences between the treatment and the placebo group (94). These variations and
inconsistencies in the current data for B vitamins suggest interaction with other dietary
factors may be modulating their impact on colorectal cancer.
Vitamins A (retinol), C (ascorbic acid), and E (tocopherols) are often studied in
combination because of their known antioxidant activities, but their impact on CRC
development has not been established conclusively. For instance, a recent study of 816
CRC cases and 815 controls from the Fukuoka Colorectal Cancer Study showed that
women with the highest retinol intake had significantly lower risk, while risk for men
was not significantly different (95). However, carotene, vitamin C, and vitamin E intakes
were not associated with CRC risk in either men or women. These results contradict the
findings of a separate study that used data from the North Carolina Colon Cancer StudyPhase II, which determined that the highest quartiles of β-carotene intake (another form
of vitamin A) were inversely associated with reduced risk of distal CRC risk in whites,
but not in African Americans (96). In this same study, a strong decrease in distal CRC
was observed in whites in the highest quartile for vitamin C, selenium, and food-derived
vitamin E intake, but not in the group that included vitamin E supplementation. In an
xenograft study by Park and colleagues (97), nude immunodeficient mice were injected
with human CRC cells (HCT-116) and then fed diets containing 2,400 or 200,000 IU
vitamin A/kg. In this experiment, vitamin A supplementation caused a 4-fold reduction in
metastatic tumor multiplicity, although tumor size and morphology were unaffected. A
separate study examined the effects of combined vitamin excess or deficiency in
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C57Bl/6J mice or ApcMin/+ mice (98). Animals were fed either a control diet, a vitamindepleted diet (reduced to 33% of the recommended daily allowance [RDA] for mice), or
a vitamin-supplemented diet (vitamin content increased by 5-fold compared to RDAs for
mice); the vitamins modified included all of the B vitamins as well as vitamins A, C, D,
E, and K. Interestingly, these researchers observed that the number and size of colon
polyps were significantly higher for both experimental diets, suggesting that both
conditions of vitamin deficiency and excess supplementation were harmful in terms of
CRC risk. Moreover, this work also underscores the notion that supplementation of diet
with high levels of vitamins, either individually or in combination, may not be the best
strategy for CRC prevention.

Modeling the Western diet in animal studies
As outlined above, many components of a typical Western style diet have been
shown to modulate cancer risk. Yet, in the vast majority of pre-clinical animal studies to
investigate mechanisms of carcinogenesis or cancer prevention or to identify new
strategies for dietary cancer prevention, researchers routinely employ standard formulated
diets that are generally balanced with respect to macro- and micronutrient levels to
optimize animal health, such as the American Institute of Nutrition AIN93G diet
formulation (99). However, these optimally formulated rodent diets are not relevant to
most human nutrition patterns, especially for at-risk populations that frequently consume
energy-dense, nutrient-poor foods. Thus, researchers have employed several different
strategies to model the Western style diet in studies employing rodents to assess impact
of diet on disease risk and/or development. One such approach is the “cafeteria” diet, in
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which the animals are allowed free access to standard chow and water, and are
concurrently offered highly palatable, energy dense, unhealthy human foods ad libitum
(100). This dietary protocol promotes hyperphagia, rapid weight gain, increased fat pad
mass, and biomarkers of metabolic syndrome and diabetes, such as glucose intolerance
and insulin resistance. Some experts argue that the cafeteria diet has limited value as an
experimental model because of difficulty in replicating the specific dietary conditions
across experiments or laboratories and because it is poorly defined with respect to
micronutrient composition (100, 101).
In a series of studies over the past twenty years, Newmark and colleagues have
employed a selective approach in modeling the Western diet, wherein specific
components of the diet are modified to emulate typical U.S. intakes (81, 102, 103). In
their first study, Newmark et al. developed a “stress” diet, which was quite low in
calcium and vitamin D3, and modestly reduced in phosphate compared to the reference
diet AIN76; also, the stress diet contained 20% fat as corn oil (40% of calories) compared
to only 5% (12% of calories) in the reference diet (102). A subsequent study extended
this stress diet to incorporate dietary components necessary for generation of methyl
donors (folic acid, methionine, choline, and vitamin B12) and determined that this new
Western diet (NWD) also enhanced spontaneous tumor development in aged C57BL/6J
mice, an effect that was reversed when calcium and vitamin D were added back to the
stress diet (81, 103). Although this series of studies has convincingly demonstrated a role
for dietary calcium and vitamin D3 in modulating spontaneous colon carcinogenesis in
mice, the scope of the diet remained limited in that it does not consider possible
contribution of the dietary fat source, carbohydrates or proteins and does not reflect
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typical human nutrition patterns for other key micronutrients, such as sodium, selenium,
or vitamins A or E. Commercial Western diets have also been developed for the study of
obesity; these diets (refered to as diet-induced obesity, or DIO, diets) typically contain
45% or 60% of energy as fat and differ from the AIN93G diets primarily in their high
lard and sucrose content (104). Although these high fat diets effectively induce obesity in
rodents (105), they are extreme in their sugar and fat compositions when compared to a
typical Western dietary pattern and do not differ substantially from AIN93G diets in
micronutrient content (104).
Importantly, none of the approaches described above for modeling typical
Western nutrition appropriately considered the contribution of suboptimal micronutrient
intakes in their disease models. To address this resource gap, our research team
developed the new total Western diet (TWD) for rodents with energy and nutrient
profiles that emulate a typical Western diet using available U.S. survey data (NHANES).
The new TWD was formulated using a nutrient density approach, described in detail in a
recent publication by members of our research group in the Journal of Agricultural and
Food Sciences (106). Briefly, the amount of each macro- and micronutrient in the
AIN93G basal diet, a diet routinely used in cancer studies today, was adjusted to match
50th percentile intakes for Americans as reported in NHANES survey data. These mass
amounts were then adjusted for caloric intake. Overall, the TWD is not necessarily
extreme in the level of any given nutrient, but rather reflects the overall dietary pattern of
the U.S. The TWD has fewer calories from protein and carbohydrate sources, and twice
that from fat as compared to the AIN93G diet. The new diet contains more saturated and
monounsaturated fats, less polyunsaturated fat, more complex carbohydrates, and twice
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the level of simple sugars. The TWD has less calcium, copper, folate, thiamine, and
vitamins B6, B12, D, and E, but much more sodium. This newly devised diet that better
represents typical U.S. nutrition is highly useful for studies employing animal models of
human cancer. For example, results of a preliminary experiment in A/J mice initiated
with AOM indicate that the TWD markedly enhanced development of preneoplastic ACF
compared to the reference diet AIN93G (107).

Project objectives and hypotheses
The objectives of this thesis project were as follows: 1) to investigate the impact
of dietary macronutrients (protein, carbohydrate, and fat) and micronutrients (vitamins
and minerals) on biomarkers of metabolic syndrome and 2) to determine the relative
importance of the macro- and micronutrient composition of the typical Western diet on
colon cancer risk using a mouse model of inflammation-associated colorectal
carcinogenesis. This study was designed to test the following working hypotheses:
1. Mice consuming the TWD will acquire a metabolic syndrome phenotype,
indicated by increased body weight, glucose intolerance, and insulin resistance, in
a manner similar to the prototypical commercial high-fat diet (45% fat DIO diet)
routinely used for diet-induced obesity pre-clinical studies.
2. TWD consumption will promote colon tumorigenesis in the C57BL/6J strain of
mouse, which is highly susceptible to diet-induced obesity and metabolic
syndrome.
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3. Tumorigenesis in mice fed TWD will be more severe (greater number of and
larger tumors) compared to mice consuming the standard basal diet AIN93G,
which was formulated to be optimal for rodent health.
4. Tumor outcome will be more severe in mice fed TWD (reflecting typical U.S.
nutrition with respect to both macro- and micronutrients) than in mice consuming
a diet modified for macronutrient content only. In other words, a typical Western
micronutrient profile will exacerbate the expected adverse effects of a high-fat,
high-sugar diet on colon carcinogenesis.
5. The new TWD will be at least as effective, if not more so, in promoting colon
carcinogenesis as the DIO diet (high fat only).
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MATERIALS AND METHODS

Chemicals
AOM was purchased from Sigma-Aldrich (St. Louis, MO; CAS No. 25843-45-2),
and reagent grade DSS was purchased from MP Biomedicals (Solon, OH; MW=36,00050,000 Da). Phosphate buffered saline (PBS) solution was purchased from Caisson Labs
(Logan, UT), and 10% buffered neutral formalin was purchased from VWR (Houston,
TX). All other chemicals used were of reagent grade and purchased from general
laboratory suppliers.

Animals
The Utah State University Institutional Animal Care and Use Committee
approved all procedures for the handling and treatment of mice used in this study
(protocols #2063 and #2114). Animals were housed in the Laboratory Animal Research
Center (LARC) at Utah State University, which is an AAALAC approved facility. Mice
were maintained in a pathogen-free vivarium at 18 to 23 °C with a 12:12 hour dark:light
cycle and humidity between 20 to 50%. Mice were provided Bed-o’Cobs® 1/4 bedding
(Andersons, Cincinnati, OH). Mice initiated with AOM were housed in HEPA-filtered
cages on a IVC Air Handling Solutions ventilated housing system (Tecniplast,
Buguggiate, Italy), while all other mice were housed in wire top cages within a ventilated
Duo-Flo BioClean Unit (Lab Products, Inc.). Male C57BL/6J mice were obtained from
Jackson Laboratories (Bar Harbor, ME) at 4 wk of age and acclimated to the vivarium for
1 wk, during which time mice were provided free access to food and water.
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Experimental diets
Experimental test diets were obtained from Harlan-Teklad (Madison, WI). To
determine the relative impact of dietary macro- and micronutrient composition on
metabolic health and cancer outcome, we compared 5 different diet formulations as
outlined in Table 1 and briefly described below:
1) AIN93G, the standard diet routinely employed in rodent cancer studies
2) The new total Western diet (TWD), as described in Hintze et al. (106)
3) A macronutrient-modified diet (MM), which contained the same
carbohydrate, protein, and lipid content as in the TWD, yet retained the
vitamin and mineral profile of the reference AIN93G diet
4) A vitamin- and mineral-modified diet (VMM), which matched the AIN93G
diet for macronutrient content, yet contained a vitamin and mineral profile
matching the TWD
5) A commercial diet-induced obesity diet (DIO) that contained 45% of energy
as fat (primarily lard) and matched the AIN93G for micronutrient content.
Diets were obtained as a single lot from the vendor and maintained at 4 °C for the
duration of the study. Fresh food was provided to mice twice per wk.

Experimental design
This study was performed in sequential parts, in which the treatment of sham
mice preceding treatment of AOM+DSS-initiated mice. Sham mice were housed
individually, whereas mice to be initiated with AOM were housed 5 animals per cage. At
5 wk of age, mice were randomly assigned to one of the experimental diet groups
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TABLE 1. Composition of experimental diets
Nutrient

AIN93G

TWD

VMM

MM

DIO

3.8
4.4
3.7
4.4
4.6
Energy density (kcal/g)
Macronutrient
Carbohydrates (g/kg diet)
Corn starch
398
230
398
230
85
Maltodextrin
132
70
132
70
115
Sucrose
100
261
100
261
200
Cellulose
50
30
50
30
58
kcal (% of total)
60.1%
54.5%
60.1%
54.5%
36.2%
Proteins (g/kg)
Casein
200
190
200
190
245
L-cystine
3
2.8
3
2.8
3.5
kcal (% of total)
18.8%
15.4%
18.8%
15.4%
19.0%
Fats (g/kg)
Soybean oil
70
31.4
70
31.4
30
Anhydrous milk fat
36.3
36.3
Olive oil
28.0
28.0
Lard
28.0
28.0
195
Beef tallow
24.8
24.8
Corn oil
16.5
16.5
Cholesterol
0.4
0.4
kcal (% of total)
17.2%
34.5%
17.2%
34.5%
44.8%
Micronutrients
Minerals (mg/kg)
Calcium
5000
2011
2011
5000
5000
Phosphorus
3000
2757
2757
3000
3000
Sodium
1019
7078
7078
1019
1019
Potassium
3600
5333
5333
3600
3600
Magnesium
507
589
589
507
507
Iron
35
31
31
35
35
Zinc
30
25
25
30
30
Copper
6
2.6
2.6
6
6
Selenium
0.15
0.2
0.2
0.15
0.15
Vitamins (unit/kg)
Thiamin (mg)
5
3.5
3.5
5
5
Riboflavin (mg)
6
4.4
4.4
6
6
Niacin (mg)
30
50.6
50.6
30
30
Pyridoxine (mg)
6
3.9
3.9
6
6
Folate (mg)
2
1.3
1.3
2
2
Vitamin B12 (μg)
25
11
11
25
25
Vitamin A (IU)
4000
4300
4300
4000
4000
Vitamin D (IU)
1000
391
391
1000
1000
Vitamin E (IU)
75
24.6
24.6
75
75
Vitamin K (μg)
750
189
189
750
750
Choline (mg)
1027
648
648
1027
1027
Note: Abbreviations for experimental diets are as follows: total Western diet, TWD; vitamin- and
mineral-modified diet, VMM; macro-modified diet, MM; and diet-induced obesity diet, DIO.
Composition of the TWD was published previously (106). No data are available in NHANES for
chloride, manganese, iodine, pantothenic acid, biotin, or ultra-trace minerals. Thus, levels of these
components in the AIN93G diet were used in the formulation of all experimental diets.
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described above (N=10 per diet group for sham mice, N=30 per diet group for
AOM+DSS-initiated mice). For AOM mice, individual animals were tracked using ear
tags and/or ear punch. Fresh food was provided twice per wk, and food consumption was
monitored at each change. Individual body weights were recorded once per wk for all
mice. Body composition of sham mice was determined by MRI scan (EchoMRI-700;
EchoMRI, Houston, TX) every 4 wk. At 7 wk of age, mice were administered with either
a subcutaneous injection of 10 mg/kg body weight AOM or sham with an equivalent
amount of the PBS vehicle. Mice initiated with AOM were also provided 1% DSS via
their drinking water for 4 wk, then tap water for the remainder of the study. Sham mice
were provided tap water for the entire study period. After a total of 16 wk on the
experimental diets, all mice were euthanized by CO2 asphyxiation and necropsied.
At necropsy of all mice, the liver, kidneys, spleen, and heart were collected,
weighed, and fixed in 10% buffered neutral formalin. Additionally, to assess fat
distribution in sham mice, the subcutaneous, gonadal, mesenteric, and retroperitoneal fat
pads were excised and weighed. Whole blood was obtained from sham mice by cardiac
venipuncture, and serum was collected by centrifugation (10,000 × g) for 5 min using
serum separation spin tubes (Sarstedt, Newton, NC). Serum was aliquoted into triplicate
cryotubes, immediately frozen in liquid nitrogen, and stored at -80°C for analysis of
plasma hormone concentrations. To assess tumor outcome in AOM+DSS-initiated mice,
colon tissues were collected from 20 mice per diet group were collected. (Tissue samples
from the remaining 10 AOM mice per group were preserved for other analyses not
reported here). Colons were rinsed with PBS, slit open longitudinally from the cecum to
the anus, placed flat between paper towels, and stored in 70% ethanol solution at 4°C.
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Fasting glucose and glucose tolerance in sham mice
Fasting glucose was assessed in sham mice every 4 wk for the duration of the
study. After a morning fasting period of 6 h, approximately 0.2 μl blood was drawn from
a 1 mm cut on the tail tip. Glucose was measured using a standard glucose meter and
glucose strips (Total Diabetes Supply, Boca Raton, FL) in triplicate for each animal. Oral
glucose tolerance tests were performed on sham mice at wk 7 and 15 of the study.
Following a morning 6 h fasting period, baseline glucose levels were obtained as
described above. Then, mice were given a bolus of 10 mg/kg glucose delivered into the
stomach by gavage needle (22 gauge, 3.81 cm long straight, 2.25 ball diameter). Plasma
glucose was again measured in triplicate at 0, 15, 30, 60, and 120 min after oral gavage.
The homeostatic model assessment (HOMA) method was used to assess insulin
resistance in fasted sham mice using the formula, HOMA = [glucose × insulin]/405,
where glucose is measured in mass units mg/dL and insulin is expressed as mU/L.

Plasma hormone levels in sham mice
In order to assess the impact of the experimental diets on biomarkers of
inflammation and glucose metabolism, 17 plasma circulating hormones were selected for
analysis: adiponectin, interleukin 2 (IL-2), IL-10, IL-6, monocyte chemotactic protein-1
(MCP-1), insulin, C-peptide, ghrelin, gastric intestinal peptide (GIP), glucagon-like
peptide 1, glucagon, leptin, pancreatic polypeptide, peptide YY, resistin, tumor necrosis
factor alpha (TNFα), and amylin. Serum samples from the sham mice were analyzed
using a Bio-Plex suspension array system (Bio-Rad Laboratories Inc., Hercules, CA)
according to the manufacturer’s supplied protocol with no deviation.
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Assessment of tumorigenesis in AOM+DSS-initiated mice
To determine the effect of the experimental diets on colorectal carcinogenesis,
colon samples were analyzed under a dissecting microscope and tumors were counted.
The researcher was blinded to the sample identification at the time of assessment.
Measurements of colon length and tumor volumes were obtained using a pair of
electronic calipers. Tumors were identified and counted using the following criteria: 1)
defined, generally round or oval shape, 2) defined, easily distinguishable edges, and 3)
lighter color with respect to surrounding tissue. Each tumor was measured for length,
height, and width. Tumor multiplicity was calculated as the number of tumors per mm
colon for each tumor-bearing animal. Colon volume was estimated using the formula,
tumor volume = π/6(L×W×D), where L is the length, W is the width, and D is the depth of
the tumor.
ACF were identified in using criteria described previously (32, 43). Briefly, ACF
were characterized as crypts of larger size and often slit-shaped, with increased
pericryptal area, and thickened layer of epithelial cells which sometimes resulted in
greater staining around the crypt. Colon tissues were stained in methylene blue for
approximately 30 sec to facilitate detection of ACF. Colon samples were coded so that
the corresponding treatment group was not known by the researcher assessing the number
of foci and the number of crypt cells per foci.

Statistical analyses
Statistical analyses for food intake, energy intake, body weight, relative organ
weights, metabolic efficiency, percentage fat and lean mass, fasting glucose, glucose
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tolerance, plasma hormone concentration, HOMA, tumor multiplicity, tumor volume (log
transformed), ACF number, and total crypts were performed using mixed models analysis
of variance (Mixed procedure, SAS 9.3) with the Satterthwaite degrees of freedom
approximation when needed to account for unequal variances among experimental
groups. Data for sham or AOM+DSS-initiated mice were analyzed independently, as the
key experimental question of interest was not the impact of AOM exposure, but rather the
impact of experimental diet on biomarkers of metabolic health and colon carcinogenesis.
For analysis of data from AOM+DSS-initiated mice, the parameter cage was included as
a random factor nested within each diet group to account for cage effects on outcomes.
Analysis of colon tumor incidence was performed using a quasi-likelihood logistic
regression (SAS genmod procedure). Finally, all analyses included the Bonferroni
multiple comparison adjustment to account for multiple testing.
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RESULTS

Food and energy intakes
Food intakes are reported on a per wk basis (Fig. 1A-B) or for the entire 16 wk
feeding period (Fig. 1C-D) for individual sham mice or on a per cage basis for
AOM+DSS-initiated mice. Results of the statistical analyses for food and energy intakes
by mice fed different experimental diets are presented in Table 2. Over the course of the
16 wk feeding period, sham and mice fed the AIN93G or VMM diets consumed
significantly more total food (9 to 16% increase for AIN93G group, 8 to 15% increase for
VMM group) compared to their counterparts fed the TWD, MM or DIO diets (P < 0.05,
Fig. 1). Although AOM+DSS-initiated mice were group housed, on a per cage basis, the
same pattern was evident on a per-cage basis, where mice fed the AIN93G and VMM
diets generally consumed more total food than mice provided TWD, MM or DIO diets
(Fig. 1). Also of note was the observation that mice that were group housed consistently
consumed less food than mice that were individually housed, even though food was
maintained at sufficient amounts in the AOM+DSS cages throughout the study.
Energy intakes were calculated using the specific energy density for each
experimental diet and the recorded food intake values on a per wk basis (Fig. 2A-B) and
for the entire 16 wk feeding period (Fig. 2C-D). In sham mice, total energy intake for
animals consuming AIN93G, TWD, or VMM diets was not significantly different (Fig.
2A,C). On the other hand, energy intakes for mice fed either the MM or DIO diets were
markedly higher (>5%) compared to all other diet groups (P < 0.05) (Fig. 2A,C; Table 2).
The pattern of energy intakes across diet groups was slightly different for
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FIGURE 1. Food consumption in sham or AOM+DSS-initiated mice. Mean food
intake per wk ± SEM is shown for sham mice (N = 10 individuals) (A) or mice initiated
with AOM+DSS (N = 4 cages, data normalized by number of mice per cage) (B). Total
food consumption data for each diet group are represented in box-and-whisker plots (plus
symbol indicates the treatment group mean and whiskers are 1.5 times the interquartile
range) for sham (C) or AOM+DSS-initiated mice (D). Different letters indicate that
treatment groups are significantly different as determined by ANOVA (SAS mixed
procedure with Satterthwaite approximation); Bonferroni-adjusted P values for multiple
comparisons among diet groups for sham and AOM+DSS-initiated mice are provided in
Table 2.
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FIGURE 2. Energy intake in sham or AOM+DSS-initiated mice. Mean energy intake
per wk ± SEM is shown for sham mice (N = 10 individuals) (A) or AOM+DSS-initiated
mice (N = 4 cages, data normalized by number of mice per cage) (B). Total energy intake
data for each diet group are represented in box-and-whisker plots (plus symbol indicates
the treatment group mean and whiskers are 1.5 times the interquartile range) for sham (C)
or AOM+DSS-initiated mice (D). Different letters indicate that treatment groups are
significantly different as determined by ANOVA (SAS mixed procedure with
Satterthwaite approximation); Bonferroni-adjusted P values for multiple comparisons
among diet groups for sham and AOM+DSS-initiated mice are provided in Table 2.
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TABLE 2. Comparisons among diet groups for food and energy intakes.
Sham
Comparison
AIN93G vs. TWD
AIN93G vs. VMM
AIN93G vs. MM
AIN93G vs. DIO
TWD vs. VMM
TWD vs. MM
TWD vs. DIO
VMM vs. MM
VMM vs. DIO
MM vs. DIO

AOM+DSS-initiated

Food intake

Energy intake

Food intake

Energy intake

<0.0001
1.0000
<0.0001
0.0005
<0.0001
0.0309
0.0062
0.0004
0.0021
1.0000

1.0000
0.9568
0.1645
<0.0001
1.0000
0.0231
<0.0001
0.0013
<0.0001
0.0527

<0.0001
1.0000
<0.0001
<0.0001
<0.0001
1.0000
0.0415
<0.0001
<0.0001
1.0000

<0.0001
0.0165
<0.0001
<0.0001
<0.0001
0.9118
<0.0001
<0.0001
<0.0001
<0.0001

Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed
procedure) with the Satterthwaite method to approximate degrees of freedom to account
for apparent unequal variances in parameter measurements among diet groups. For
AOM+DSS-initiated mice, analyses of food and energy intakes were performed using
cage data, rather than individual data for AOM+DSS-initiated mice; for all other
parameters, cage was considered as a random factor nested within the diet treatment
group. P values of the differences of least squares means are shown for each pair-wise
comparison among diet groups, and significant differences are shown in bold.

AOM+DSS-initiated mice. As in sham mice, energy intake values (normalized to the
number of mice per cage) were not significantly different between AIN93G and VMM
groups, and both of these groups had lower energy intakes than mice fed MM or DIO
diets (Fig. 2D). However, unlike sham mice, energy intake for AOM+DSS-initiated
animals fed TWD and MM was similar and significantly higher than those fed AIN93G
(P < 0.0001). These differences in the patterns of food and energy intake among diet
groups could be attributed to food competition, as AOM+DSS mice were housed in
groups of 4 to 5 mice during the study. Regardless, as with sham mice, the AOM+DSSinitiated mice fed the DIO diet consumed significantly more calories (>11%) than all
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other groups (P<0.0001). Conversely, AOM+DSS-initiated mice fed the VMM
consumed fewer calories than all other diet groups (P<0.05), reflecting the differences in
energy density of the diets.

Body weight, organ weights, and metabolic efficiency
Sham and AOM+DSS-initiated mice gained weight steadily throughout the entire
study period, although the rate of weight gain (and food consumption) for AOM+DSSinitiated mice was slightly lower for all diet groups in the week following carcinogen
injection (Fig. 3A-B). At the conclusion of the study, final body weights for mice
consuming TWD or VMM diets were not different for mice fed the reference AIN93G
diet, yet they were significantly lower (P <0.05) than mice fed either the MM or DIO
diets (Fig. 3C; Tables 3 and 4). A similar pattern was observed for mice initiated with
AOM (Fig. 3D). Sham or AOM+DSS-initiated mice fed the DIO diet gained about 10 or
13% more weight, respectively, than their counterparts consuming the AIN93G reference
diet. However, average final body weights were approximately 19% higher in DIO-fed
mice (sham and AOM+DSS-initiated) than mice provided the VMM diet, representing
the largest difference in body weight gain among the experimental diet groups.
In general, the weights of liver, kidney, and spleen with respect to body weight
were not markedly affected by dietary treatment, with a few notable exceptions. The
average relative liver weight for mice that consumed the DIO diet was marginally lower
(0.47 to 0.58%) compared to all other diet groups (P < 0.05); this pattern was also evident
in AOM+DSS-initiated mice, though only significant between DIO and AIN93G or
TWD groups (P = 0.0208 and 0.0002, respectively). However, the absolute liver weights
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FIGURE 3. Body weight gain in sham or AOM+DSS-initiated mice. Values for body
weight gain over time ± SEM are shown for sham (N = 10) (A) or AOM+DSS-initiated
mice (N = 30) (B). Final body weight data for each diet group are represented in box-andwhisker plots (plus symbol indicates the treatment group mean, and whiskers are 1.5
times the interquartile range) for sham (C) or AOM+DSS-initiated mice (D). Different
letters indicate that treatment groups are significantly different as determined by ANOVA
(SAS mixed procedure with Satterthwaite approximation); Bonferroni-adjusted P values
for multiple comparisons among diet groups for sham and AOM+DSS-initiated mice are
provided in Table 4.

Body
weight (g)

Liver
weight (g)

Relative liver
weight (%)

Kidney
weight (mg)

Relative kidney
weight (%)

Spleen
weight (mg)

Relative spleen
weight (%)

Sham
AIN93G
28.4±1.4
1.06±0.086
3.74±0.22
367±23
1.30±0.10
74.0±9.7
0.261±0.031
TWD
26.4±1.5
1.00±0.082
3.77±0.18
387±24
1.47±0.12
68.0±9.2
0.259±0.040
VMM
26.4±3.2
0.993±0.12
3.78±0.50
366±37
1.39±0.071
78.0±13
0.297±0.052
MM
30.0±2.4
1.10±0.076
3.67±0.20
376±25
1.26±0.085
74.0±9.7
0.247±0.030
DIO
31.4±3.7
0.998±0.11
3.20±0.38
424±38
1.36±0.12
73.0±14
0.231±0.023
AOM+DSS-initiated
AIN93G
25.3±1.7
1.09±0.12
4.30±0.42
341±33
1.35±0.11
85.7±15
0.340±0.063
TWD
26.5±1.6
1.20±0.15
4.51±0.48
382±41
1.44±0.11
188±104
0.711±0.40
VMM
25.2±1.7
1.08±0.13
4.29±0.51
358±40
1.42±0.14
148±101
0.590±0.42
MM
28.7±2.5
1.18±0.17
4.12±0.42
391±50
1.36±0.11
80.3±12
0.281±0.045
DIO
30.3±2.0
1.14±0.14
3.76±0.35
438±67
1.45±0.23
85.7±19
0.284±0.065
Note: Values shown are average body and organ weights or the relative liver, kidney and spleen weights (organ weight ÷ body weight × 100) ±
standard deviation for each treatment group (N = 10 for Sham groups; N = 30 for AOM groups).

Diet group

TABLE 3. Body organ weights for sham- and AOM+DSS-initiated mice.
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BW (g) BW gain (g) LW (%) KW (%) SW (%)

BW (g)

BW gain (g) LW (%) KW (%) SW (%)

AOM+DSS-initiated

AIN93G vs. TWD
1.0000
0.6970
1.0000
1.0000
0.3025
1.0000
1.0000
1.0000 <0.0001
0.0039
AIN93G vs. VMM 0.9905
0.6970
1.0000
0.4313
0.3080
1.0000
1.0000
1.0000
1.0000
0.0010
AIN93G vs. MM
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
<0.0001
0.0002
AIN93G vs. DIO
0.1141
1.0000
0.7296
0.3986
1.0000
0.0413
0.0038
<0.0001
<0.0001
0.0208
TWD vs. VMM
1.0000
1.0000
1.0000
0.8588
0.2176
0.2023
0.4877
0.8501
1.0000
0.7674
TWD vs. MM
1.0000
1.0000
0.3606
1.0000 <0.0001
0.0331
0.0141
0.0002
0.0053
0.0054
TWD vs. DIO
0.1675
0.9821
1.0000 <0.0001
0.0009
0.0001
0.0026
<0.0001
<0.0001
0.0002
VMM vs. MM
1.0000
1.0000
1.0000 <0.0001
0.0316
0.0141
0.0450
0.0343
<0.0001
<0.0001
VMM vs. DIO
1.0000
0.0880
1.0000 <0.0001
0.0008
0.0001
0.0016
0.0019
<0.0001
<0.0001
MM vs. DIO
1.0000
1.0000
0.2856
1.0000
0.0570
0.1504
0.2683
1.0000
1.0000
0.0183
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure) with the Satterthwaite method to approximate
degrees of freedom to account for apparent unequal variances in parameter measurements among diet groups. P values of the differences of least
squares means are shown for each pair-wise comparison among diet groups, and significant values are shown in bold. Abbreviations are as
follows: body weight, BW; liver weight, LW; kidney weight, KW; and spleen weight, SW.

Comparison

Sham

TABLE 4. Comparisons among diet groups for body and relative organ
weights for sham- and AOM+DSS-initiated mice.
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were not different among diet groups (P > 0.05), suggesting that the difference in relative
liver weight values was a reflection not of a change in liver health status, but rather the
body weight of mice consuming the DIO diet. Average relative spleen weight was
markedly higher (up to 2-fold) in mice consuming TWD or VMM diets compared to
other diet groups (P ≤ 0.001), although this trend was not observed in sham mice (Tables
3, 4).
Metabolic efficiency was calculated for only sham mice, which were singly
housed (Fig. 4). Animals fed the MM and DIO diets had significantly lower metabolic
efficiency that TWD and VMM-fed mice, suggesting that they were less efficient and
converting nutrients into energy. However, neither the MM nor DIO diet groups differed
significantly from the AIN93-fed animals. Also, metabolic efficiency values for mice
consuming diets modified in vitamin and mineral content (TWD and VMM diets) were
not significantly different from mice fed AIN93G.

Body composition and fat distribution
To determine the impact of the experimental diets on fat accumulation, the body
composition of sham mice was assessed periodically by MRI (Tables 5,6). In general, the
rate of lean mass gain among any of the experimental diet groups was similar, and the
average final lean mass was the same for all groups (Fig. 5A). However, when calculated
as a percentage of body weight, lean mass at the end of the study was slightly lower in
mice consuming the MM or DIO diets compared to the VMM diet (P<0.05), yet average
percentage lean mass was not significantly different for any of the test diet groups
compared to the reference AIN93G diet group (Fig. 5C). On the other had, a markedly
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different pattern was observed for effect of diet on fat accumulation over time (Fig. 5B).
At the end of the study, the average fat mass of mice fed either the MM or DIO diets was
7 to 12% higher compared to mice fed TWD or VMM (Fig. 5D). A comparison of the
relative lean and fat mass gain among experimental groups shows that the apparent
differences in body weight gain in MM and DIO animals was attributed entirely to an
increase in fat mass.

FIGURE 4. Metabolic efficiency in sham mice. A, Mean metabolic efficiency
(calculated as weekly energy intake divided by weekly body weight gain) is shown ±
SEM (N = 10 individuals). B, Values for cumulative metabolic efficiency (total energy
intake divided by total body weight gain) are represented in box-and-whisker plots (plus
symbol indicates the treatment group mean and whiskers are 1.5 times the interquartile
range). Different letters indicate that treatment groups are significantly different as
determined by ANOVA (SAS mixed procedure with Satterthwaite approximation to
account for apparent unequal variances); Bonferroni-adjusted P values for multiple
comparisons among diet groups are provided in Table 5.

39
TABLE 5. Body composition in sham mice.
Diet Group

Week 0

Week 4

Week 8

Week 12

Week 16

Fat mass
AIN93G
1.88±1.06
2.53±0.43
3.09±1.31
3.64±0.64
5.34±1.38
TWD
2.22±0.51
2.58±0.22
2.43±0.35
3.63±0.60
4.52±1.06
VMM
2.16±0.64
2.59±0.41
2.85±0.70
3.33±1.01
4.14±1.41
MM
2.72±0.62
3.12±0.49
3.60±0.47
5.38±1.50
7.13±1.92
DIO
2.14±0.52
2.95±0.75
4.68±1.34
6.16±1.98
8.64±2.88
Lean mass
AIN93G
15.32±1.13 17.70±0.79 17.97±1.68 20.63±0.40 19.99±2.11
TWD
15.33±1.00 16.75±0.74 18.26±0.51 19.75±0.59 19.52±0.93
VMM
15.03±1.55 16.86±1.59 18.97±1.36 19.36±1.67 19.99±1.35
MM
14.50±1.56 17.34±0.43 19.04±0.45 19.62±0.86 20.26±1.21
DIO
15.67±0.80 17.49±0.90 18.97±1.00 20.31±1.81 20.48±1.17
Note: Values shown are the average fat or lean mass (g) determined by EchoMRI ± SD for each
treatment group (N = 10).

TABLE 6. Comparisons among diet groups for
body composition in sham mice.
Lean mass
Fat mass
Comparison
g
% of BW
g
% of BW
AIN93G vs. TWD
1.0000
1.0000
1.0000
1.0000
AIN93G vs. VMM
1.0000
0.6791
1.0000
0.9477
AIN93G vs. MM
1.0000
1.0000
0.3509
0.4761
AIN93G vs. DIO
1.0000
0.5086
0.0023
0.0082
TWD vs. VMM
1.0000
1.0000
1.0000
1.0000
TWD vs. MM
1.0000
0.2837
0.0282
0.0377
TWD vs. DIO
1.0000
0.0628
<0.0001
0.0003
VMM vs. MM
1.0000
0.0204
0.0074
0.0051
VMM vs. DIO
1.0000
0.0034
<0.0001
<0.0001
MM vs. DIO
1.0000
1.0000
0.7317
1.0000
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure)
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal
variances in parameter measurements among diet groups. Effects of diet treatment on final lean or
fat weights (g) and relative weights (%) are were determined separately. P values of the
differences of least squares means are shown for each pair-wise comparison among diet groups,
and significant values are shown in bold.

40

FIGURE 5. Body composition of sham mice. Body composition was assessed by MRI
at wk 0, 4, 8, 12, and 16. The change in lean (A) and fat (B) mass for each diet group over
time is shown ± SEM (N = 10 individuals). Values for the lean mass (C) and fat mass (D)
with respect to final body weight (fat mass ÷ body weight × 100) are represented in boxand-whisker plots (plus symbol indicates the mean for the treatment group, and whiskers
are 1.5 times the interquartile range). Different letters indicate that treatment groups are
significantly different as determined by ANOVA (SAS mixed procedure with
Satterthwaite approximation to account for apparent unequal variances); Bonferroniadjusted P values for multiple comparisons among diet groups are provided in Table 8.
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To determine the impact of experiment diet on fat distribution, we assessed the
relative mass of subcutaneous, gonadal, mesenteric, and retroperitoneal fat pads with
respect to final body weight of sham mice at the conclusion of the experiment (Tables 7,
8). A significant increase in the average percent fat mass was observed for all fat types, in
animals that consumed either the MM or DIO diets, whereas no significant differences
were apparent for mice fed AIN93G, TWD or VMM (Fig. 6). This effect of diet was
most notable for subcutaneous fat, which was twice as abundant in mice fed DIO diet
compared to the AIN93G, TWD or VMM diets (P < 0.0001). Additionally, a significant
difference in the ratio of subcutaneous to visceral (gonadal, retroperitoneal, and
mesenteric) fat was observed when comparing mice fed AIN93G (0.66 ratio) to those that
consumed the DIO diet (0.91 ratio) (P <0.01), whereas this ratio was not different among
mice fed either the TWD, VMM or MM diets.

Fasting glucose and glucose tolerance in sham mice
To assess the impact of experimental diets on biomarkers of metabolic syndrome,
we measured fasting glucose and oral glucose tolerance periodically throughout the study
in a subset of 6 mice randomly selected from each treatment group. At the start of the
study, average fasting glucose levels were similar for all treatment groups (Fig. 7), and
this trend among treatment groups was fairly consistent throughout the experiment (Table
9). At the conclusion of the study, average fasting glucose levels were not significantly
different compared between the reference AIN93G diet and the other experimental diet
groups (Fig. 7C). However, fasting glucose was elevated in DIO-fed mice compared to
those that consumed the VMM diet (P = 0.0043).

g

% of BW

g

% of BW

Gonadal
g

% of BW

Mesenteric
g

% of BW

Retroperitoneal
Ratio

AIN93G
0.88±0.21 3.09±0.65
0.73±0.18 2.55±0.56
0.42±0.06 1.46±0.16
0.20±0.05 0.69±0.15
0.66±0.13
TWD
0.90±0.22 3.37±0.66
0.63±0.13 2.37±0.38
0.39±0.04 1.48±0.15
0.20±0.07 0.74±0.23
0.73±0.067
VMM
0.91±0.28 3.38±0.72
0.57±0.18 2.13±0.47
0.43±0.08 1.62±0.22
0.17±0.12 0.63±0.34
0.75±0.25
MM
1.51±0.57 4.93±1.81
1.09±0.29 3.58±0.77
0.53±0.09 1.75±0.19
0.38±0.12 1.26±0.31
0.77±0.052
DIO
2.09±0.71 6.50±1.41
1.20±0.43 3.70±0.97
0.62±0.14 1.95±0.24
0.49±0.18 1.53±0.40
0.91±0.11
Note: Values shown are the average weight or the average relative weight for each fat deposit (fat pad weight ÷ body weight × 100) ± SD for
each treatment group (N = 10). The ratio of subcutaneous to visceral fat was calculated as the mass of subcutaneous fat ÷ (mass of gonadal +
mesenteric + retroperitoneal fats).

Diet Group

Subcutaneous

TABLE 7. Fat deposition in sham mice.
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TABLE 8. Comparisons among diet groups for
fat distribution in sham mice.
Comparison

Subcutaneous
(% of BW)

Gonadal
(% of BW)

Mesenteric
(% of BW)

Retroperitoneal
(% of BW)

AIN93G vs. TWD
1.0000
1.0000
1.0000
1.0000
AIN93G vs. VMM
1.0000
1.0000
1.0000
0.6698
AIN93G vs. MM
0.0079
0.0107
0.0011
0.0174
AIN93G vs. DIO
<0.0001
0.0007
<0.0001
<0.0001
TWD vs. VMM
1.0000
1.0000
1.0000
1.0000
TWD vs. MM
0.0389
0.0017
0.0033
0.0366
TWD vs. DIO
<0.0001
<0.0001
<0.0001
<0.0001
VMM vs. MM
0.0412
0.0001
0.0002
1.0000
VMM vs. DIO
<0.0001
<0.0001
<0.0001
0.0023
MM vs. DIO
1.0000
0.1211
0.1265
0.0087
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure)
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal
variances in parameter measurements among diet groups. P values of the differences of least
squares means are shown for each pair-wise comparison among diet groups, and significant
values are shown in bold.

Glucose tolerance was assessed by calculating the area under the curve (AUC) for
oral glucose tolerance tests performed at wk 7 and 15 of the study (Fig. 8). Values for
AUC for the DIO group were significantly higher (by about 50%) than mice fed the
AIN93G and VMM diets at both time points assessed (Fig. 8; Table 9), but other dietary
treatment groups did not alter glucose tolerance in comparison to the reference AIN93G
diet.

Plasma hormone levels in sham mice
At the conclusion of the study, levels of a variety of hormones critical to
regulation of food intake, inflammation, and development of metabolic syndrome were
measured in blood samples collected from sham mice. Seven in the multiplex assay were
reliably detected in all samples, including adiponectin, resistin, leptin, insulin, GIP,
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FIGURE 6. Fat distribution in sham mice. Values for the percentage subcutaneous (A),
gonadal (B), mesenteric (C), and retroperitoneal fat (D) and the ratio of subcutaneous fat
to visceral fat (including gonadal, mesenteric and retroperitoneal) (E) are represented in
box-and-whisker plots (plus symbol indicates the mean for the treatment group, and
whiskers are 1.5 times the interquartile range). Different letters indicate that treatment
groups are significantly different as determined by ANOVA (SAS mixed procedure with
Satterthwaite approximation to account for apparent unequal variances); Bonferroniadjusted P values for multiple comparisons among diet groups are provided in Table 7.
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FIGURE 7. Fasting glucose levels in sham mice. Fasting glucose was determined at the
start of the study, then again at wk 4, 8, 12, and 16 (A). The change in fasting glucose for
each diet group over time is shown ± SEM (N = 6). Values for fasting glucose at wk 0 (B)
and at wk 16 (C) are represented in box-and-whisker plots (plus symbol indicates the
mean for the treatment group, and whiskers are 1.5 times the interquartile range).
Different letters indicate that treatment groups are significantly different as determined
by ANOVA (SAS mixed procedure with Satterthwaite approximation to account for
apparent unequal variances); Bonferroni-adjusted P values for multiple comparisons
among diet groups for each time point are provided in Table 9.
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TABLE 9. Comparisons among diet groups for fasting glucose levels
and oral glucose tolerance in sham mice.
Fasting glucose
Comparison

Wk 0

Wk 4

Wk 8

Wk 12

oGTT
Wk 16

Wk 7

Wk 15

AIN93G vs. TWD 1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
AIN93G vs. VMM 1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
AIN93G vs. MM
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
AIN93G vs. DIO
1.0000
1.0000
0.3022
0.0477
0.0395
0.0477
0.0395
TWD vs. VMM
1.0000
1.0000
1.0000
1.0000
0.3628
1.0000
1.0000
TWD vs. MM
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
TWD vs. DIO
0.1054
0.1202
1.0000
1.0000
1.0000
0.1054
0.1202
VMM vs. MM
1.0000
1.0000
1.0000
1.0000
0.1589
1.0000
1.0000
VMM vs. DIO
1.0000
0.7892
0.0277
0.0137
0.0043
0.0277
0.0137
MM vs. DIO
0.1403
0.2396
1.0000
1.0000
1.0000
0.1403
0.2396
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure)
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal
variances in parameter measurements among diet groups. P values of the differences of least
squares means are shown for each pair-wise comparison among diet groups, and significant
values are shown in bold.

C-peptide, and IL-6, while the levels of the other 10 hormones were below the detection
limit of the assay. For the most part, the experimental diets did not significantly impact
circulating hormone levels (Fig. 9). Two notable exceptions included leptin, which was
elevated in mice fed DIO approximately 2-fold compared to mice provided the AIN93G,
VMM or TWD diets (P < 0.01); plasma leptin levels were also elevated in mice fed the
MM diet compared to mice consuming the AIN93G, TWD, and VMM diets (Fig. 9C).
Lastly, plasma levels of GIP were significantly higher in mice consuming TWD
compared to the VMM-fed animals, although neither group were significantly different
from the reference AIN93G diet or the DIO diet group (Fig. 9D). Finally, the HOMA
method was used to calculate insulin resistance, which was significantly higher in mice
fed the DIO diet compared to those fed TWD (P < 0.01), although neither group was
significantly different from the AIN93G, VMM or MM groups (Fig. 10)
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FIGURE 8. Oral glucose tolerance in sham mice. Results of oral glucose tolerance
tests at wk 7 (A) and wk 15 (B) are shown. Symbols represent mean glucose levels ±
SEM (N = 6). Glucose tolerance was assessed by calculating the area under the curve
(AUC) with baseline set at 100 mg/dL. Calculated AUC values for oGTT at wk 7 (C) and
at wk 15 (D) are represented in box-and-whisker plots (plus symbol indicates the mean
for the treatment group, and whiskers are 1.5 times the interquartile range). Different
letters indicate that treatment groups are significantly different as determined by ANOVA
(SAS mixed procedure with Satterthwaite approximation to account for apparent unequal
variances); Bonferroni-adjusted P values for multiple comparisons among diet groups for
each time point are provided in Table 5.
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FIGURE 9. Plasma hormone levels in sham mice. Mean plasma concentrations of
adiponectin (A), resistin (B), leptin (C), gastric inhibitory peptide (GIP) (D), insulin (E),
c-peptide (F) and IL-6 (G) are shown ± SEM (N = 6 to 10). Different letters indicate that
treatment groups are significantly different as determined by ANOVA (SAS mixed
procedure with the Bonferroni adjustment for multiple comparisons).
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FIGURE 10. Insulin resistance by the homeostatic model assessment (HOMA)
method. HOMA was calculated using matched values for fasting glucose and insulin at
16 wk as described in Methods. Average HOMA values are shown ± SEM (N = 6).
Different letters indicate that treatment groups are significantly different as determined
by ANOVA (SAS mixed procedure with the Bonferroni adjustment for multiple
comparisons).

Impact of experimental diets on colon tumorigenesis
The most critical objective of this study was to assess the impact of experimental
diet on colorectal carcinogenesis. At the end of the feeding trial, the number of
preneoplastic lesions and the incidence, abundance and size of colon tumors were
determined in a subset of mice initiated with AOM+DSS (N = 20) (Tables 10, 11).
Values for all of these parameters are expressed on a colon length basis, as colon tissues
with high tumor burden tend to be shorter in length and thus have less surface area. As
expected with this initiation protocol, nearly all animals fed the reference AIN93G diet
acquired colon cancer. However, tumors were detected in only 80% of the mice fed DIO
diet, which was marginally significantly different (P=0.0479) from the 100% cancer
incidence observed in mice fed TWD, VMM or MM diets (Table 10).
On the other hand, striking significant effects of experimental diet on tumor
multiplicity and size were observed. Mice provided either the TWD or VMM diets had
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nearly twice as many tumors as their AIN93-fed counterparts (P< 0.01), and about 3times the number of tumors as animals provided the MM or DIO diets (P <0.0001) (Fig.
11A). However, tumor multiplicity was not significantly different in animals fed the MM
or DIO diets compared to the AIN93G group.
A very similar pattern for tumor volume was also evident, as the average tumor
size in mice provided TWD or VMM diets was about 3.6- to 2.5-fold higher than in mice
fed AIN93G diet (P <0.01) (Fig. 11B). An even more pronounced increase in tumor
volume was observed, a nearly 10-fold difference, when comparing the TWD and VMM
groups to mice fed MM or DIO diets (P < 0.0001). Moreover, average tumor volumes in
mice fed TWD and VMM were significantly greater than tumor volume for the reference
AIN93G group (P = 0.0009 and 0.022, respectively).
To determine whether mice fed MM or DIO diets acquired a large number of
preneoplastic lesions that failed to progress to tumors, we counted the average number of
aberrant crypts and the number of ACF (Fig. 11C-D) (Table 10). No significant
differences among diet groups were observed (Table 11), although the low variance
evident in the TWD and VMM likely reflects that many of the preneoplastic in these diet
groups progressed to form colon tumors.

Incidence *

Multiplicity †
Volume §

Aberrant crypt foci ¶

Total crypts ‡

Aberrant crypts

AIN93G
95% (19/20) a,b
0.0701±0.0089 a
1.53±0.24 a
0.0375±0.0110 a
0.0597±0.014 a
TWD
100% (19/19) a
0.124±0.014 b
5.49±0.76 b
0.0172±0.0033 a
0.0294±0.0064 b
a
b
b
a
VMM
100% (19/19)
0.139±0.014
3.80±0.65
0.0353±0.0028
0.0382±0.0029 b
a
a
c
a
MM
100% (19/19)
0.0308±0.0039
0.41±0.10
0.0318±0.0044
0.0508±0.0062 a
b
a
c
a
DIO
80% (16/20)
0.0470±0.0041
0.51±0.13
0.0406±0.0081
0.0660±0.012 a
Note: Analysis of tumor incidence was performed using a quasi-likelihood logistic regression (SAS genmod procedure), while tumor multiplicity,
tumor volume (log-transformed), number of aberrant crypt foci and number of total crypts were analyzed using a mixed model ANOVA (SAS
mixed procedure) with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal variances in parameter
measurements among diet groups. Different letters indicate that the treatment groups are significantly different. P values of the differences of least
squares means for each pair-wise comparison among diet groups are available in Table 7.
* Values are the percent incidence (cases/total) for each dietary group. Twenty mice were originally allocated to each diet group for assessment of
tumor outcome, although one mouse each in the TWD, VMM, and MM diet groups died within 48 h of AOM injection due to the well-known
toxic effects of this carcinogen.
†
Tumor multiplicity was calculated as the average number of tumors per tumor-bearing animal normalized to the colon length. Values shown are
mean tumor multiplicity per mm colon ± SEM.
§
Tumor size was estimated using the equation Volume = π/6(L×W×D). Values shown are the mean tumor volume (mm3) ± SEM.
¶
The average number of aberrant crypt foci was calculated as the number of foci per animal bearing aberrant crypts normalized to the colon
length. Values shown are the average number of aberrant crypt foci per mm colon ± SEM .
‡
The average total number of aberrant crypts was calculated as the number of total crypts per animal bearing aberrant crypts normalized to the
colon length. Values shown are the average number of total crypts per mm colon ± SEM.

Diet group

Tumor outcome

TABLE 10. Colon tumorigenesis in mice initiated with AOM+DSS.
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TABLE 11. Comparisons among diet groups for colon tumorigenesis in mice
initiated with AOM+DSS.
Tumor outcome
Comparison

Incidence

Multiplicity

Aberrant crypts
Volume

Number foci

Total crypts

AIN93G vs. TWD
1.0000
0.6413
1.0000
0.0031
<0.0001
AIN93G vs. VMM
1.0000
1.0000
1.0000
<0.0001
0.0027
AIN93G vs. MM
1.0000
1.0000
1.0000
1.0000
0.0009
AIN93G vs. DIO
0.2982
0.1177
1.0000
1.0000
0.0220
TWD vs. VMM
1.0000
1.0000
1.0000
1.0000
1.0000
TWD vs. MM
1.0000
1.0000
1.0000
<0.0001
<0.0001
TWD vs. DIO
0.2880
0.1877
0.0479
<0.0001
<0.0001
VMM vs. MM
1.0000
1.0000
1.0000
<0.0001
<0.0001
VMM vs. DIO
1.0000
0.6011
0.0479
<0.0001
<0.0001
MM vs. DIO
1.0000
1.0000
1.0000
1.0000
0.0479
Note: Analysis of tumor incidence was performed using a quasi-likelihood logistic regression
(SAS genmod procedure), while tumor multiplicity, tumor volume (log-transformed), number of
aberrant crypt foci and number of crypts per foci were analyzed using a mixed model ANOVA
(SAS mixed procedure) with the Satterthwaite method to approximate degrees of freedom to
account for apparent unequal variances in parameter measurements among diet groups. P values
of the differences of least squares means are shown for each pair-wise comparison among diet
groups, and significant values are shown in bold.
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B

0.35

Tumors/mm colon

0.30
0.25

b

b

0.20
0.15

a
a

0.10

a

0.05

ACF/mm colon
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D

0.15

0.10

a
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a
a
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b

2

a
1

c
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MM

DIO

0
-1
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DIO

Total crypts/mm colon
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b

Tumor volume (mm3)

A
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FIGURE 11. Colon tumorigenesis in mice initiated with AOM+DSS. Tumor
multiplicity (number of tumors for tumor-bearing animals normalized by the colon
length) (A), tumor volume (calculated as V = π/6 (L×W×D) where L is length, W is width,
and D is depth) (B), aberrant crypt foci (number of foci for mice with foci) (C), and total
crypts (total number of aberrant crypts for animals with foci) (D) are represented in boxand-whisker plots (plus symbol indicates the mean for the treatment group, and whiskers
are 1.5 times the interquartile range). Different letters indicate that treatment groups are
significantly different as determined by ANOVA (SAS mixed procedure with
Satterthwaite approximation to account for apparent unequal variances); Bonferroniadjusted P values for multiple comparisons among diet groups are provided in Table 10.
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DISCUSSION

We report for the first time that a newly devised diet that recapitulates U.S.
nutrition patterns with respect to macro- and micronutrient content markedly enhanced
colorectal carcinogenesis in a mouse model of inflammation-associated colon cancer
compared to a basal diet optimized for rodent health. Moreover, we determined that the
micronutrient components of the TWD were primarily responsible for increased cancer
susceptibility in these mice. This study is the second from our group to show that this diet
functions to promote colon cancer in mice. Previously, we showed that A/J mice initiated
with AOM and fed TWD for 16 wk developed significantly more ACF and total crypt
cells than mice fed the AIN93G diet (107). Interestingly, green tea supplementation
(0.2% Polyphenon E) markedly reduced the accumulation of aberrant crypts in animals
fed the TWD, but did not alter colon carcinogenesis in animals consuming AIN93G.
These observations pointed to a complex, yet critical interaction between basal diet and
the activity of a well-established anticancer agent.
In an effort to understand better the impact of this westernized diet on cancer
susceptibility, we sought to determine the relative impacts of the macro- and
micronutrient components of the TWD on colon cancer as well as on biomarkers of
metabolic syndrome and obesity in comparison to the commercial 45% fat DIO diet. As
expected, mice consuming the DIO diet acquired an obesity/metabolic syndrome
phenotype typified by increased food energy intake, greater rate of body weight gain,
increased proportion of body composition as fat mass, higher fasting glucose, impaired
glucose tolerance, and higher circulating levels of leptin. However, the TWD did not
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significantly alter any of these classic biomarkers of metabolic health, a somewhat
surprising observation considering that this diet contains substantially more fat than the
AIN93G diet (35 compared to 17 percent of total kcal, respectively). Furthermore, our
observations also suggest that the DIO diet does not enhance colon cancer in the
AOM+DSS model, a finding somewhat contrary to prior observations for ACF in rats
(66, 108). While this later finding was admittedly unexpected, it points to the critical
need to employ a diet model that represents typical human nutrition. Had the experiment
design included only DIO diet as the model obesogenic Western diet, we could have
easily (and erroneously) concluded that colorectal cancer risk in mice was unaffected by
the Western nutrition pattern. Moreover, we would have missed the more remarkable
discovery that inappropriate micronutrient consumption strongly increased colon
tumorigenesis in this mouse model, as evidenced by highly similar results for the TWD
and the VMM diets, both of which had vitamin and mineral content that reflects typical
American nutrition. Modification of macronutrient content alone (i.e., DIO and MM
diets) did not increase colorectal carcinogenesis, an observation that also points to a
critical role for micronutrients in promoting colorectal carcinogenesis in this pre-clinical
mouse model.
Numerous studies have shown that consumption of a high fat diet promotes a gain
in relative fat mass in a dose-dependent manner (109). The higher adiposity observed in
animals fed either the MM or DIO diets reflected the relatively high fat content of these
diets (34 and 45%, respectively). However, new evidence points to a role in the source of
dietary fat for influencing fat deposition and subsequent impacts on parameters of
metabolic health. Catta-Preta et al. (110) reported that C57BL/6J mice fed a diet

56
containing 60% fat from lard or olive oil had higher levels of plasma insulin, resistin, and
leptin, compared to mice fed diets with 60% sunflower oil or canola oil. Moreover, the
ratio of subcutaneous to visceral fat was at least 40% smaller in animals fed the lard or
olive oil diets compared to animals provided diets containing other lipid sources. The fat
source for the DIO diet is primarily lard, whereas the fat content of the AIN93G and
VMM diets is exclusively soybean oil. The MM and TWD diets incorporate a variety of
fat sources relevant to typical Western nutrition, including soybean oil, milk fat, lard,
olive oil, beef tallow, and corn oil. Interestingly, in this study, the ratio of subcutaneous
to visceral fat was significantly higher in mice fed DIO compared to the reference
AIN93G diet. However, we did not detect a difference in the fat type ratio between the
DIO and MM diets, although these diets are not directly comparable due to their
difference in total fat concentration. In another study by Huang et al. (111), higher levels
of leptin and the pro-inflammatory hormones resistin, MCP-1 and CD192 were observed
in C57BL/6J mice fed a 38% safflower oil diet rich in polyunsaturated fatty acids
compared to isocaloric diets containing lard and milk fat. Our analysis of plasma
hormones also included adiponectin, resistin, insulin, GIP, C-peptide, and IL-6. These
hormones and cytokines, which are involved in energy balance and inflammation, are
important biomarkers for systemic inflammation and colorectal cancer (19, 112).
Unfortunately, the results of the hormone analysis for our study were limited because of
the high variability in measurements among mice or because plasma concentrations of
some hormones were below the assay limit of detection. However, blood plasma levels of
leptin were closely correlated with body composition, as expected for this fat-derived
hormone (113).
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The consumption of a high fat diet is strongly linked to high rates of obesity due
to increased energy intake, as opposed to greater food mass consumption (see review by
109). Observations from our study concur with this model, in that mice fed the DIO diet
had significantly greater energy intake than their AIN93G-fed counterparts, yet lower
food mass consumption. Importantly, these animals did not completely adjust their food
consumption so that their energy intake was on par with animals consuming the reference
diet. Moreover, this pattern was consistent throughout the study, indicating that DIO-fed
mice did not adequately adapt over time to the high fat content of their diet. On the other
hand, sham mice fed TWD consumed the least mass of food of any diet group, and this
decrease was sufficient to normalize their total energy intake to that of the AIN93G-fed
mice. As a consequence, mice fed the TWD did not gain excess weight nor develop
biomarkers of obesity-induced metabolic syndrome. This difference in energy intake
cannot be attributed solely to the modest 10% difference in fat content of these 2 diets, as
sham mice fed the MM diet (matched to TWD for all macronutrients) had significantly
greater food and energy intake compared to TWD-fed animals. That these observations
were not entirely consistent for AOM+DSS-initiated mice could be attributed to
competition among cage-mates or other behavior effects present in group-housed male
mice.
The results of this study indicate that micronutrients contribute to colorectal
carcinogenesis to a greater extent than do macronutrients in a mouse model of
inflammation-associated colon cancer. For many endpoints evaluated, we observed that
the data segregated into groups based on similarity in response: MM and DIO diets (with
high fat the common feature); TWD and VMM diets (with modified vitamins and
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minerals the common feature) and then the reference diet AIN93G. For endpoints
associated with obesity and metabolic syndrome, significant effects were often observed
for the MM and DIO diets, but not the others. The opposite pattern was evident for colon
cancer outcome, with significant effects of diet apparent only for mice fed TWD or MM
diets. Evidently, increased tumorigenesis in mice fed either of these diets was not linked
to higher rates of obesity or metabolic syndrome. Because the TWD models the typical
U.S. diet with respect to nearly all major micro- and macronutrient components, it is not
possible to confidently single out one (or a few) constituents responsible for its tumor
promoting effect. Nevertheless, our strategy is an important advance on prior studies that
investigated the impact of only one or a select few components of the Western diet on
colon cancer.
The nutrient density approach was previously employed by Newmark et al. (102)
to construct a Western-type diet containing the levels of fat, phosphorous, calcium, and
vitamin D observed in average American diets. Compared to the AIN76A diet, their
Western diet contained higher levels of fat and phosphorous, and lower levels of calcium
and vitamin D. C57BL/6J mice fed their Western diet promoted spontaneous hyperproliferation and hyperplasia in colonic epithelium. In a subsequent study, this further
modified this experimental diet by reducing levels of components critical for methyl
donor generation, including folic acid, methionine, and vitamin B12 (103). Consumption
of this modified western diet led to higher rates of spontaneous colon adenoma and
carcinoma development in normal mouse colon. Other number of other rodent studies
using the AOM model of CRC point to a role for high fat diet in enhancing colorectal
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carcinogenesis, even though the fat composition in these experiments varied widely (38,
63, 97, 114, 115).
Alternatively, the importance of various dietary micronutrients on CRC
development has also been shown in a number of animal and human studies. The TWD
contains low amounts of several essential micronutrients when compared to both the DIO
diet and RDA values for humans (106). On an energy density basis, amounts of vitamins
B6, B12, and folate are about 33 to 50% of the TWD compared to the AIN93G control
diet, while calcium and vitamin D levels are approximately 60% lower.
As outlined in the introduction, evidence from human epidemiological studies and
experiments in animal models points to a role for both calcium and vitamin D in
modulation of CRC (116-118). Calcium functions to regulate cellular signaling, cell
proliferation and cell growth, while vitamin D is critical for adequate uptake of calcium
in the small intestine. A 24-wk study on Apc1638N/+ mice, which have a truncation on
codon 1638 of the tumor suppressor Apc gene, found that feeding a modified AIN76A
diet with half the content of vitamin D and 90% less calcium resulted in the formation of
colonic adenomas and a carcinomas, and enhanced expression of cyclin D1 and antiapoptotic protein Bcl-2, which are commonly overexpressed in colorectal cancer (82). In
a different study using this same diet fed to C57BL/6J mice over a period of 3 and 6
months, researchers identified important transcriptome changes associated with induction
of the oxidative stress response pathway (119). Moreover, calcium and vitamin D were
determined to be important regulators of bile acid synthesis and excretion. Vitamin D has
been shown to be involved in the detoxification of bile acids through the regulation of
fibroblast growth factor 15 (120) and the vitamin D receptor (121) in the intestine, while
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calcium has been shown to increase fecal fatty acid excretion (122, 123). Bile acids
contribute to colorectal carcinogenesis by increasing cellular oxidative stress, and they
have been associated with the promotion of cell populations resistant to their apoptotic
effects (124). Bile acids are the main pathway for cholesterol catabolism in mammals,
and hence they are generally found in high levels in individuals that consume a high-fat
diet (125). Thus, the combined impact of excess fat with low calcium and vitamin D
content in the TWD could explain the promoting effect of this diet on colon
tumorigenesis observed in this study.
Choline, folate, and vitamins B6 and B12 are essential in cellular biosynthetic
pathways due to their roles as donors of methyl groups for one carbon-metabolism (84).
These micronutrients are present in the AIN93G diet at substantially greater levels than
the RDA value for humans, when compared on an energy density basis (106). Moreover,
the TWD contains substantially lower levels of these micronutrients than are present in
the AIN93G diet. A case-control study of subjects from the Multiethnic Cohort study
found that people in the highest quartile for pyridoxal-5’-phosphate intake (active form of
B6) had a 48% reduction in CRC risk (126). A meta-analysis that included 7 cohortstudies and 9 case-control studies found a 25% lower risk of CRC among those in the
highest category of dietary folate intake compared with those in the lowest category,
while only a 5% lower risk was observed for total folate intake (including supplements)
(85). An animal study using male Sprague-Dawley rats fed with either a diet with 50
μg/kg diet of vitamin B12 or a diet with no vitamin B12 found that, after 10 wk of feeding,
rats fed the deficient diet displayed a 35 percent decrease in genomic methylation and a
105 percent increase in base substitution of uracil. Although some studies have found
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weak or no association between CRC risk or development and dietary B-vitamins (87, 89,
127), the supporting evidence points to a complex interaction between other nutrients in
the diet. Also, the low levels of B-vitamins in the TWD could explain the promoting
effect on tumorigenesis observed in animals fed this diet.
In conclusion, evidence from this work supports the idea that a rodent diet more
representative of the diet consumed by the majority of Americans is necessary to
appropriately evaluate colon cancer risk and to develop specific and effective prevention
strategies. Diets that modeled Western nutrition with respect to macronutrient content
only yielded a greatly different disease phenotype than did a diet that also took into
account suboptimal micronutrient consumption. The health consequences of chronic low
intakes of multiple micronutrients are not well understood and should be studied in the
context of modern dietary patterns. To extend upon this work, our research group plans to
investigate the impact of TWD using the well-established APCMin/+ genetic mouse model
of gastrointestinal carcinogenesis. Also, our group will continue to investigate molecular
markers of colorectal carcinogenesis in colon mucosa obtained from sham and
AOM+DSS-initiated mice from this project using global gene expression microarrays
and immunohistochemistry. Finally, given the profound impact of the TWD on colon
carcinogenesis and the mounting evidence for perinatal or transgenerational impacts of
diet on cancer risk (128-135), we plan to investigate the impact of TWD provided via the
maternal diet on risk of cancer to offspring.
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